Compound profile
Also known as: LY3437943 · triple agonist
An investigational triple agonist (GLP-1, GIP, and glucagon receptors) studied for obesity and metabolic disease. Currently the highest-profile name in the space, widely framed as the next-generation successor to tirzepatide, with heavy search interest among fitness audiences.
Retatrutide, given the research code LY3437943, is a synthetic peptide engineered by Eli Lilly to activate three separate hormone receptors at once: GIP, GLP-1, and glucagon. It is built on a GIP peptide backbone that has been modified with non-standard amino acids and a long fatty diacid chain that lets it bind albumin in the blood, which is what allows once-weekly dosing. The idea behind stacking three receptor targets into one molecule is to combine the appetite and glucose effects of GIP and GLP-1 with the energy-expenditure and lipid effects associated with glucagon, in the hope of producing weight loss beyond what single or dual agonists achieve.
Retatrutide is not an approved drug. It has moved through a large clinical trial program, a phase 2 obesity trial published in the New England Journal of Medicine in 2023, a phase 2a trial in metabolic dysfunction-associated steatotic liver disease, and a phase 3 program called TRIUMPH that has reported several readouts, including a knee osteoarthritis population (TRIUMPH-4) and a large general obesity trial (TRIUMPH-1), plus a type 2 diabetes trial called TRANSCEND. As of this writing it remains investigational, with analysts and trade press expecting a possible FDA filing and approval sometime around 2027 or 2028, not before.
That combination, a genuinely large and growing human trial dataset alongside no current approval, sets retatrutide apart from most of the compounds discussed on this site. Its reputation is built substantially on real phase 2 and phase 3 human data rather than animal work, which is unusual for a research-only peptide, but it is still a drug candidate under review rather than something with an established real-world safety record outside supervised trials.
Activates GLP-1, GIP, and glucagon pathways involved in appetite regulation, glucose handling, and energy expenditure. Exact contribution of each receptor in humans is still being mapped in trials.
Retatrutide works by binding to and activating three receptors that the body normally engages separately through different gut and pancreatic hormones. Through GLP-1 and GIP, both part of the incretin system, it increases glucose-dependent insulin release, slows gastric emptying, and acts on appetite centers in the brain, mechanisms shared with dual agonists like tirzepatide and single agonists like semaglutide.
What sets retatrutide apart is the added glucagon receptor activity. Glucagon is usually thought of as insulin's counterpart, raising blood sugar, but it also increases energy expenditure and influences how the liver handles fat. Researchers believe pairing glucagon receptor activation with GIP and GLP-1 signaling is what drives the larger weight loss seen in retatrutide trials compared with dual-agonist drugs, though exactly how much each of the three receptors contributes to the overall effect in humans is still being worked out as more trial data comes in. The long fatty acid chain attached to the peptide slows its clearance from the body, supporting once-weekly dosing similar to other drugs in this class.
The phase 2 obesity trial reported dose-dependent weight loss of up to 24.2% at 48 weeks versus 2.1% with placebo, and topline phase 3 results (TRIUMPH-1) reported roughly 28% average weight loss at 80 weeks, effect sizes approaching those historically associated with bariatric surgery. Results are striking but come from supervised trial settings in defined patient groups, not general fitness use.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
The phase 2 obesity trial reported dose-dependent weight loss up to about 24% at 48 weeks versus roughly 2% with placebo, and the later phase 3 TRIUMPH-1 trial reported around 28% average weight loss at 80 weeks in a larger patient population.
The TRANSCEND-T2D trial reported meaningful HbA1c reductions alongside weight loss in adults with type 2 diabetes.
A phase 2a trial in people with metabolic dysfunction-associated steatotic liver disease (MASLD) reported reductions in liver fat content, an area of active interest for the drug class.
The TRIUMPH-4 trial, run in people with obesity and knee osteoarthritis, reported weight loss alongside improvements in pain and physical function scores after 68 weeks.
Investigational and not broadly approved for consumer use as of last review. GI side effects are common in the class, and a dose-dependent increase in heart rate was seen in phase 2. The glucagon component raises glucose and lean-mass questions worth watching. Long-term safety and off-label athletic contexts are not well characterized. Always evaluate with a clinician using primary sources.
Retatrutide is still an investigational drug candidate, not an approved medicine, and it is not legally available by prescription in the United States as of this review. Everything reported about it comes from supervised clinical trials in defined patient populations, not general fitness or off-label use, and that distinction matters because trial monitoring, dosing accuracy, and patient screening do not carry over to unregulated sourcing. Across the trial program, gastrointestinal side effects, nausea, diarrhea, vomiting, and constipation, are common and follow the same pattern seen with other incretin-based drugs, especially during dose escalation. Phase 2 data also showed a dose-dependent increase in heart rate, which researchers are continuing to track in later trials. The glucagon receptor component is mechanistically distinct from tirzepatide and semaglutide, and questions about its longer-term effects on lean mass, glucose control at higher doses, and cardiovascular parameters remain open areas of study rather than settled findings. Anyone encountering retatrutide outside a clinical trial setting is dealing with an unapproved, unregulated product, and that carries its own separate risks around purity and dosing accuracy on top of the biology itself.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Semaglutide, tirzepatide, and retatrutide are commonly compared when people research metabolic and fat-loss peptide classes, from approved GLP-1/GIP medicines to investigational triple agonists.
These are distinct molecules with different approval statuses and trial populations. Comparison talk is educational, not a recommendation to obtain or combine them.
Fat loss · Metabolic
